CASI Pharmaceuticals, Inc. (CASI) Sees Unusually-High Trading Volume

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) saw unusually-high trading volume on Tuesday . Approximately 237,000 shares changed hands during mid-day trading, an increase of 11% from the previous session’s volume of 213,433 shares.The stock last traded at $2.51 and had previously closed at $2.40.

CASI has been the topic of several recent research reports. ValuEngine upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 15th. Maxim Group restated a “buy” rating and issued a $4.00 price target on shares of CASI Pharmaceuticals in a research note on Tuesday. Finally, HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of CASI Pharmaceuticals in a research note on Friday, September 8th.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). sell-side analysts expect that CASI Pharmaceuticals, Inc. will post -0.15 earnings per share for the current fiscal year.

In other CASI Pharmaceuticals news, Director Wei-Wu He bought 315,327 shares of the business’s stock in a transaction on Friday, September 15th. The shares were acquired at an average cost of $1.33 per share, for a total transaction of $419,384.91. Following the purchase, the director now owns 212,323 shares in the company, valued at approximately $282,389.59. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have acquired 996,329 shares of company stock worth $1,647,138. Company insiders own 13.01% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was reported by Stock Observer and is owned by of Stock Observer. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Leave a Reply